Myobloc® (rimabotulinumtoxinB)

Myobloc (rimabotulinumtoxinB) is covered for adults (≥18 years) only for FDA‑approved indications—cervical dystonia and chronic sialorrhea—and for the compendial off‑label use of upper‑limb spasticity; other uses are excluded. Approvals are valid 12 months and require dosing within specified ranges (cervical dystonia 2,500–5,000 U; chronic sialorrhea 1,500–3,500 U; upper‑limb spasticity up to 20,000 U) with administration no more often than every 12 weeks.

"Treatment of cervical dystonia in adults."

Sign up to see full coverage criteria, indications, and limitations.